Ma Xiao-Bo, Zheng Yan, Yuan He-Pei, Jiang Jing, Wang Yin-Ping
Department of Pathology, The First Hospital of Jilin University, Changchun 130021, China.
Division of Clinical Epidemiology, The First Hospital of Jilin University, Changchun 130021, China.
Hum Pathol. 2015 Apr;46(4):593-9. doi: 10.1016/j.humpath.2015.01.002. Epub 2015 Jan 14.
CD43 (leukosialin) is a transmembrane glycoprotein expressed in a variety of hematopoietic cells, including B lymphocytes, and a variety of malignancies including lymphoma, leukemia, and solid tumors. CD43 plays an important role in the development of many diseases, and coexpression of CD43 and CD20 on peripheral B cells is a predictive factor of hematopoietic malignancy. Although CD43 is expressed in approximately 25% of diffuse large B-cell lymphomas (DLBCLs), its prognostic significance remains unclear. To analyze CD43 expression in DLBCL, not otherwise specified (DLBCL, NOS), and assess its prognostic value, we analyzed clinical data from 160 patients with DLBCL, NOS. We observed that CD43 expression was detected in 47 (29.4%) of 160 cases. CD43 expression was positively correlated with old age (>60 years), high serum lactate dehydrogenase level, B symptoms, non-germinal center type, and DLBCL, NOS, mortality. Patients with CD43-positive DLBCL, NOS, had poorer overall survival (P < .001, log-rank test) and event-free survival (P < .001, log-rank test) than CD43-negative patients. Univariate analysis showed that CD43 expression, age, sex, Ann Arbor stage, International Prognostic Index category, and germinal center phenotype were prognostic factors for DLBCL, NOS, patient survival. Multivariate analysis showed that CD43 expression was an independent significant prognostic factor for event-free survival (P < .001) and overall survival (P < .001). Based on these data, we conclude that CD43 expression is a novel adverse prognostic factor for patients with DLBCL, NOS.
CD43（白细胞唾液酸蛋白）是一种跨膜糖蛋白，在包括B淋巴细胞在内的多种造血细胞以及包括淋巴瘤、白血病和实体瘤在内的多种恶性肿瘤中表达。CD43在许多疾病的发生发展中起重要作用，外周B细胞上CD43和CD20的共表达是造血系统恶性肿瘤的一个预测因素。尽管CD43在大约25%的弥漫性大B细胞淋巴瘤（DLBCL）中表达，但其预后意义仍不清楚。为了分析未另行规定的DLBCL（DLBCL，NOS）中CD43的表达情况，并评估其预后价值，我们分析了160例DLBCL，NOS患者的临床资料。我们观察到，160例病例中有47例（29.4%）检测到CD43表达。CD43表达与老年（>60岁）、血清乳酸脱氢酶水平高、B症状、非生发中心型以及DLBCL，NOS死亡率呈正相关。CD43阳性的DLBCL，NOS患者的总生存期（P <.001，对数秩检验）和无事件生存期（P <.001，对数秩检验）比CD43阴性患者差。单因素分析显示，CD43表达、年龄、性别、Ann Arbor分期、国际预后指数类别和生发中心表型是DLBCL，NOS患者生存的预后因素。多因素分析显示，CD43表达是无事件生存期（P <.001）和总生存期（P <.001）的独立显著预后因素。基于这些数据，我们得出结论，CD43表达是DLBCL，NOS患者的一个新的不良预后因素。
